GlassScriptPhysician profile
Johnson L Moon
NPI 1457407579
$10,098.01
in general payments reported to CMS, 2019-2025
44 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $154 · 2021: $771 · 2022: $5,053 · 2023: $895 · 2024: $1,766 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,920 · Travel and Lodging: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,920.11 |
| Travel and Lodging | $605.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $2,404.64 | 2021-2024 | Ocrevus |
| Biogen, INC. | $2,305.77 | 2021-2023 | Vumerity, Avonex |
| Abbott Laboratories | $1,269.11 | 2024-2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $953.84 | 2019-2025 | |
| Abbvie INC. | $700.97 | 2021-2025 | |
| Csl Behring | $293.49 | 2020-2025 | Hizentra |
| Ucb, INC. | $289.22 | 2022-2025 | Briviact, Nayzilam |
| Astrazeneca Pharmaceuticals LP | $247.82 | 2019-2021 | |
| Lilly USA, LLC | $126.07 | 2021-2024 | Emgality, Kisunla, Reyvow |
| Acadia Pharmaceuticals INC | $123.08 | 2023-2025 | Nuplazid |
| Actelion Pharmaceuticals US, INC. | $122.14 | 2019 | |
| Allergan, INC. | $120.25 | 2020-2022 | |
| Celgene Corporation | $109.74 | 2022-2025 | Zeposia |
| Mdd US Operations, LLC | $92.93 | 2022-2024 | Apokyn, Gocovri |
| Banner Life Sciences, LLC | $81.13 | 2021-2022 |
Show all 40 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnson Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.